New radiation therapy shows promise for slowing neuroendocrine tumors
NCT ID NCT02743741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called Lu-DOTATATE, which delivers radiation directly to neuroendocrine tumor cells. About 195 people with tumors that have gotten worse will receive up to 4 cycles of this therapy, with doses adjusted based on individual scans and blood tests. The main goal is to see how many patients remain cancer-free one year after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
London Health Sciences Centre
London, Ontario, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
-
Sunnybrook Odette Cancer Center
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial